Advancements in Multiple Myeloma Treatment: Insights from Clinical Trials in Asia-Scilight

Trends in Immunotherapy

Review

Advancements in Multiple Myeloma Treatment: Insights from Clinical Trials in Asia

Downloads

https://doi.org/10.54963/ti.v9i2.1055
Ting Fang Tang, Chin Sum Cheong, Nur Adila Anuar, Won Fen Wong, & Gin Gin Gan. (2025). Advancements in Multiple Myeloma Treatment: Insights from Clinical Trials in Asia. Trends in Immunotherapy, 9(2), 157–172. https://doi.org/10.54963/ti.v9i2.1055
Volume. 9, Issue. 2 ( 2025)
Copyright (c) 2025 Ting Fang Tang, Chin Sum Cheong, Nur Adila Anuar, Won Fen Wong, Gin Gin Gan
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Ting Fang Tang

    Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
  • Chin Sum Cheong

    Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
  • Nur Adila Anuar

    Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
  • Won Fen Wong

    Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
  • Gin Gin Gan

    Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia

Received: 13 March 2025; Revised: 1 April 2025; Accepted: 9 April 2025; Published: 9 June 2025

Multiple myeloma (MM) is one of the most common hematological cancers characterized by the abnormal expansion of clonal plasma cells, resulting in the secretion of abnormal monoclonal proteins and disruption of normal hematopoiesis in human bone marrow. Despite historically lower prevalence than in Western nations, an increasing incidence of MM has been noted in Asian countries. In recent years, the therapeutic landscape of MM has undergone a major transformation with the development of proteasome inhibitors (PIs) and monoclonal antibodies (mAbs), which have now emerged as cornerstones of treatment. PIs such as bortezomib, carfilzomib, and ixazomib selectively inhibit the proteasome, disrupting protein homeostasis in myeloma cells and inducing apoptosis. Bortezomib, the first-in-class PI, revolutionized MM therapy, while second-generation inhibitors like carfilzomib and ixazomib have improved potency and safety profiles. mAbs, including anti-CD38 agents (daratumumab and isatuximab) and the anti-SLAMF7 agent (elotuzumab), have markedly enhanced survival outcomes by specifically attacking myeloma cells and promoting immune-mediated destruction. Daratumumab, in particular, has shown exceptional efficacy both as monotherapy and in combination regimens, leading to its widespread adoption in frontline and relapsed/refractory MM (RRMM) settings. Other emerging therapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are revolutionizing MM management. CAR T-cell therapy, particularly BCMA-targeted constructs, has yielded impressive clinical outcomes in RRMM but is limited by manufacturing challenges, toxicities, and durability of response. Bispecific antibodies, which simultaneously target myeloma cells and T cells, offer promising efficacy. Additionally, newer drug classes, including selective nuclear export inhibitors, histone deacetylase inhibitors, and novel small-molecule inhibitors, are being explored to overcome resistance mechanisms. This review provides a comprehensive overview of MM pathophysiology and disease progression, with a focus on the landscape of treatment strategies in Asian countries.

Keywords:

Asia; Clinical Trials; Immunomodulatory Drugs (IMiDs); Multiple Myeloma; Monoclonal Antibodies (mAbs); Proteasome Inhibitors (PIs)

References

  1. Lemaire, M., Deleu, S., De Bruyne, E., et al. The microenvironment and molecular biology of the multiple myeloma tumor. Adv. Cancer Res. 2011, 110, 19–42.
  2. Rajkumar, S.V. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2018, 93, 981–1114.
  3. Lo, C., Nguyen, S., Yang, C., et al. Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications. Clin. Transl. Sci. 2020, 13, 861–870.
  4. Landgren, O., Gridley, G., Turesson, I., et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006, 107, 904–906.
  5. Kim, K., Lee, J.H., Kim, J.S., et al. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Am. J. Hematol. 2014, 89, 751–756.
  6. Wang, S., Xu, L., Feng, J., et al. Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis. Front. Oncol. 2019, 9, 1513.
  7. Cowan, A.J., Allen, C., Barac, A., et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018, 4, 1221–1227.
  8. Tang, C.H., Hou, H.A., Huang, K.C., et al. Treatment evolution and improved survival in multiple myeloma in Taiwan. Ann. Hematol. 2020, 99, 321–330.
  9. Kazandjian, D. Multiple myeloma epidemiology and survival: A unique malignancy. In Seminars in oncology; Elsevier: Amsterdam, The Netherlands, 2016.
  10. Ravi, P., Kumar, S.K., Cerhan, J.R., et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018, 8, 26.
  11. Tamura, H. Immunopathogenesis and immunotherapy of multiple myeloma. Int. J. Hematol. 2018, 107, 278–285.
  12. Bahlis, N.J., Dimopoulos, M.A., White, D.J., et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020, 34, 1875–1884.
  13. Suzuki, K., Dimopoulos, M.A., Takezako, N., et al. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer J. 2018, 8, 41.
  14. Hungria, V., Beksac, M., Weisel, K.C., et al. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. Br. J. Haematol. 2021, 193, 561–569.
  15. Mateos, M.V., Sonneveld, P., Hungria, V., et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin. Lymphoma Myeloma Leuk. 2020, 20, 509–518.
  16. Sonneveld, P., Chanan-Khan, A., Weisel, K., et al. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J. Clin. Oncol. 2023, 41, 1600–1609.
  17. Attal, M., Richardson, P.G., Rajkumar, S.V., et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019, 394, 2096–2107.
  18. Sunami, K., Suzuki, K., Ri, M., et al. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study. Cancer Sci. 2020, 111, 4526–4539.
  19. Huang, S.Y., Yoon, S.S., Shimizu, K., et al. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis. Adv. Ther. 2020, 37, 3404–3416.
  20. Ma, Y., Xiao, X.B., Liu, Y.S., et al. Analysis of the efficacy and safety of bone disease treatment in patients with newly diagnosed multiple myeloma treated with denosumab or zoledronic acid. Zhonghua Xue Ye Xue Za Zhi 2024, 45, 345–350.
  21. Sunami, K., Iida, S., Tsukada, N., et al. DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma. Int. J. Hematol. 2025, 121, 174–186.
  22. Cortes-Selva, D., Perova, T., Skerget, S., et al. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study. Blood 2024, 144, 615–628.
  23. Moreau, P., Garfall, A.L., van de Donk, N., et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 2022, 387, 495–505.
  24. Iida, S., Ito, S., Yokoyama, H., et al. Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3. Jpn. J. Clin. Oncol. 2024, 54, 991–1000.
  25. Huang, S.Y., Yu, Y.B., Yeh, S.P., et al. A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan. J. Formos. Med. Assoc. 2017, 116, 705–710.
  26. Hou, J., Du, X., Jin, J., et al. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. J. Hematol. Oncol. 2013, 6, 41.
  27. Suzuki, K., Shinagawa, A., Uchida, T., et al. Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study. Cancer Sci. 2016, 107, 653–658.
  28. Kobayashi, T., Miura, M., Niioka, T., et al. Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide. Ther. Drug. Monit. 2018, 40, 301–309.
  29. Bahlis, N.J., Corso, A., Mugge, L.O., et al. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia 2017, 31, 2435–2442.
  30. Lu, J., Lee, J.H., Huang, S.Y., et al. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br. J. Haematol. 2017, 176, 743–749.
  31. Soekojo, C.Y., Kim, K., Huang, S.Y., et al. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. Blood Cancer J. 2019, 9, 83.
  32. Lee, H.S., Kim, K., Kim, S.J., et al. Korean Multiple Myeloma Working, P. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). Am. J. Hematol. 2020, 95, 413–421.
  33. Sunami, K., Matsue, K., Suzuki, K., et al. Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. Cancer Sci. 2020, 111, 2116–2122.
  34. Teoh, G., Chen, Y., Kim, K., et al. Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma. Clin. Lymphoma Myeloma Leuk. 2012, 12, 118–126.
  35. Zhao, W.H., Wang, B.Y., Chen, L.J., et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J. Hematol. Oncol. 2022, 15, 86.
  36. Xu, J., Chen, L.J., Yang, S.S., et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc. Natl. Acad. Sci. USA 2019, 116, 9543–9551.
  37. Mei, H., Li, C., Jiang, H., et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J. Hematol. Oncol. 2021, 14, 161.
  38. Wang, D., Wang, J., Hu, G., et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood 2021, 137, 2890–2901.
  39. Qu, X., An, G., Sui, W., et al. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. J. Immunother. Cancer 2022, 10, e005145.
  40. Yan, Z., Cao, J., Cheng, H., et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019, 6, e521–e529.
  41. Wang, Y., Cao, J., Gu, W., et al. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J. Clin. Oncol. 2022, 40, 2246–2256.
  42. Li, C., Cao, W., Que, Y., et al. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Clin. Transl. Med. 2021, 11, e346.
  43. Du, J., Wei, R., Jiang, S., et al. CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status. Am. J. Hematol. 2022, 97, 933–941.
  44. Munshi, N.C., Anderson, L.D.Jr; Shah, N., et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N. Engl. J. Med. 2021, 384, 705–716.
  45. Diaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., et al. Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers (Basel) 2021, 13, 1353.
  46. Bonello, F., Grasso, M., D'Agostino, M., et al. The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Pharmaceuticals (Basel) 2020, 14, 20.
  47. Fujisaki, T., Ishikawa, T., Takamatsu, H., et al. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. Ann. Hematol. 2019, 98, 2805–2814.
  48. Mateos, M.V., Cavo, M., Blade, J., et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020, 395, 132–141.
  49. Mateos, M.V., Nahi, H., Legiec, W., et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020, 7, e370–e380.
  50. Kawano, Y., Kim, K., Min, C.K., et al. Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis. Clin. Lymphoma Myeloma Leuk. 2023, 23, e360–e367.
  51. Kim, K., Min, C.K., Koh, Y., et al. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. Int. J. Hematol. 2022, 116, 553–562.
  52. Moreau, P., Dimopoulos, M.A., Yong, K., et al. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. Future Oncol. 2020, 16, 4347–4358.
  53. Dimopoulos, M.A., Dytfeld, D., Grosicki, S., et al. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J. Clin. Oncol. 2023, 41, 568–578.
  54. Dimopoulos, M.A., Lonial, S., White, D., et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020, 10, 91.
  55. Dimopoulos, M.A., Richardson, P.G., Bahlis, N.J., et al. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022, 9, e403–e414.
  56. Iida, S., Nagai, H., Kinoshita, G., et al. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. Int. J. Hematol. 2017, 105, 326–334.
  57. Cohen, Y.C., Magen, H., Gatt, M., et al. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 2025, 392, 138–149.
  58. Chang, X., Zhu, Y., Shi, C., et al. Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim. Biophys. Sin. (Shanghai) 2014, 46, 240–253.
  59. Merz, M., Dechow, T., Scheytt, M., et al. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Ann. Hematol. 2020, 99, 1709–1725.
  60. Raedler, L.A. Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma. Am. Health Drug Benefits 2016, 9, 140–143.
  61. Dimopoulos, M., Weisel, K., Moreau, P., et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia 2021, 35, 1722–1731.
  62. Carpenter, R.O., Evbuomwan, M.O., Pittaluga, S., et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 2013, 19, 2048–2060.
  63. Brudno, J.N., Maric, I., Hartman, S.D., et al. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J. Clin. Oncol. 2018, 36, 2267–2280.
  64. Huang, S.Y., Chen, T.Y., Kuo, C.Y., et al. Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma. Oncol. Rev. 2019, 13, 377.
  65. Ahn, J.S., Jung, S.H., Yang, D.H., et al. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 2014, 14, 389–394.
  66. Kobayashi, T., Kuroda, J., Shimura, K., et al. Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. Int. J. Hematol. 2010, 92, 579–586.
  67. Lee, H.S., Kim, Y.S., Kim, K., et al. Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. J. Korean Med. Sci. 2013, 28, 80–86.
  68. Tan, D., Kim, K., Kim, J.S., et al. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leuk. Res. 2013, 37, 1070–1076.
  69. Kiba, T., Ito, T., Nakashima, T., et al. Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. BMC Cancer 2014, 14, 462.
  70. Laubach, J.P., Schjesvold, F., Mariz, M., et al. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021, 22, 142–154.
  71. Cavenagh, J., Oakervee, H., Baetiong-Caguioa, P., et al. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Br. J. Cancer 2017, 117, 1295–1302.
  72. Ri, M., Iida, S., Maruyama, D., et al. HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1). Cancer Sci. 2021, 112, 5011–5019.
  73. Orlowski, R.Z., Moreau, P., Niesvizky, R., et al. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin. Lymphoma Myeloma Leuk. 2019, 19, 522–530+e521.
  74. Dimopoulos, M.A., Moreau, P., Iida, S., et al. Outcomes for Asian patients with multiple myeloma receiving once-or twice-weekly carfilzomib-based therapy: A subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Int. J. Hematol. 2019, 110, 466–473.
  75. Dimopoulos, M., Quach, H., Mateos, M.V., et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020, 396, 186–197.
  76. Facon, T., Lee, J.H., Moreau, P., et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2019, 133, 1953–1963.
  77. Gupta, N., Goh, Y.T., Min, C.K., et al. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J. Hematol. Oncol. 2015, 8, 103.
  78. Hou, J., Jin, J., Xu, Y., et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J. Hematol. Oncol. 2017, 10, 137.
  79. Suzuki, K., Handa, H., Chou, T., et al. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. Int. J. Hematol. 2017, 105, 445–452.
  80. Qiu, L., Xia, Z., Fu, C., et al. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. BMC Med. 2022, 20, 108.
  81. Richard, S., Chari, A., Delimpasi, S., et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am. J. Hematol. 2021, 96, 1120–1130.
  82. Suzuki, K., Sunami, K., Matsumoto, M., et al. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. Acta. Haematol. 2021, 144, 264–274.
  83. Obeng, E.A., Carlson, L.M., Gutman, D.M., et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107, 4907–4916.
  84. Ito, S. Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers 2020, 12, 265.
  85. Lee, S.R., Choi, H., Lee, B.H., et al. Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. Korean J. Intern. Med. 2019, 34, 1333–1346.
  86. Moreau, P., Masszi, T., Grzasko, N., et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 2016, 374, 1621–1634.
  87. Takakuwa, T., Yamamura, R., Ohta, K., et al. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. Eur. J. Haematol. 2021, 106, 555–562.
  88. Chari, A., Vogl, D.T., Gavriatopoulou, M., et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N. Engl. J. Med. 2019, 381, 727–738.
  89. Richard, S., Jagannath, S. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy. BioDrugs 2022, 36, 13–25.
  90. Andreu-Vieyra, C.V., Berenson, J.R. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther. Adv. Hematol. 2014, 5, 197–210.
  91. Mateos, M.V., Gavriatopoulou, M., Facon, T., et al. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. J. Hematol. Oncol. 2021, 14, 59.
  92. Nishimura, K.K., Barlogie, B., van Rhee, F., et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020, 4, 422–431.
  93. Ikeda, T., Mori, K., Kawamura, K., et al. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. Hematol. Oncol. 2019, 37, 586–594.
  94. Kawamura, K., Tsukada, N., Kanda, Y., et al. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma. Biol. Blood Marrow. Transplant. 2018, 24, 1392–1398.
  95. Kikuchi, T., Mori, T., Koda, Y., et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Int. J. Hematol. 2015, 102, 670–677.
  96. Muranushi, H., Kanda, J., Kobayashi, M., et al. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial. Hematology 2022, 27, 239–248.
  97. Rajkumar, S.V., Jacobus, S., Callander, N.S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010, 11, 29–37.
  98. Fuchida, S.I., Sunami, K., Matsumoto, M., et al. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma. Int. J. Hematol. 2019, 109, 107–114.
  99. Takamatsu, H., Munemoto, S., Murata, R., et al. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma. Anticancer Res. 2013, 33, 5681–5685.
  100. Ueda, T., Iino, R., Yokoyama, K., et al. Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population. Int. J. Hematol. 2012, 96, 477–484.